fda semaglutide compounding enforcement november 2025 Judge Upholds Deadline Ending Production of Compounded Ozempic and Wegovy FDA's GLP-1 decision kicks off
Description
R., Tavares R., et al
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management
doi: 10.1136/bmj.i6505
GLP-1 weight loss treatment is generally appropriate for adults with a BMI of 30 or higher, or 27 or higher with weight-related comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease
The Bronx and Staten Island have fewer options, which makes telehealth especially valuable if you're based there
